Skip to main content

United StatesBreaking News

Grafa

Merck secures FDA breakthrough status for Calderasib and Keytruda lung cancer combination

Merck (NYSE:MRK) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to its investigational oral drug calderasib when paired with the company’s blockbuster immunotherapy Keytruda, accelerating its development path for newly diagnosed lung cancer patients.

Read more